References
- Kim JH, Zamorano J, Erdine S, et al; on behalf of the CRUCIAL Investigators. Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (<65 years) and older (≥65 years) patients in the CRUCIAL trial. Curr Med Res Opin 2013;29:1-11
- Athyros VG, Katsiki N, Tziomalos K, et al.; for the GREACE Study Collaborative Group. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE Study. Arch Med Sci 2013 [in press]
- Athyros VG, Tziomalos K, Gossios TD, et al; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet 2010;376:1916-22
- Athyros VG, Ganotakis E, Kolovou GD, et al; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative. Assessing the treatment effesct in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011;9:647-57
- Athyros VG, Karagiannis A, Ganotakis ES, et al; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011;27:1659-68
- Athyros VG, Papageorgiou AA, Kontopoulos AG. Statin–fibrate combinations in patients with combined hyperlipidemia. Atherosclerosis 2001;155:263-4
- Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-202
- Katsiki N, Athyros VG, Karagiannis A. Single-pill combinations: a therapeutic option or necessity for vascular risk treatment? J Drug Assessment 2013 [in press]
- Kjeldsen SE, Messerli FH, Chiang CE, et al. Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin 2012;28:1685-97
- Levin P, Wei W, Wang L, et al. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin 2012;28:439-46
- Kaku K, Enya K, Sugiura K, et al. Efficacy and safety of combination therapy with candesartan cilexetil and pioglitazone hydrochloride in patients with hypertension and type 2 diabetes mellitus. Curr Med Res Opin 2011;27(Suppl 3):73-84